Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 03, 2025 08:41 ET | Source: Janssen Cilag International NV

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care,...
June 25, 2025 13:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

Hernia Repair Devices Market is Set to Attain Valuation of US$ 6.57 Billion by 2033 | Astute Analytica

Chicago, June 25, 2025 (GLOBE NEWSWIRE) -- The global hernia repair devices market was valued at US$ 4.69 billion in 2024 and is projected to reach US$ 6.57 billion by 2033, growing at a CAGR of...
June 20, 2025 06:39 ET | Source: Janssen Cilag International NV

IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase 3 TRIANGLE study results by the European MCL...
June 20, 2025 06:34 ET | Source: Janssen Cilag International NV

DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease...
June 19, 2025 07:00 ET | Source: Wood Mackenzie

With the US data center pipeline surging regulated utilities are proving advantaged in meeting demand, says Wood Mackenzie

PRESS RELEASE With the US data...
June 15, 2025 03:15 ET | Source: Janssen Cilag International NV

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel,...
June 12, 2025 02:00 ET | Source: Janssen Cilag International NV

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free...
June 03, 2025 11:05 ET | Source: Janssen Cilag International NV

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in...
June 03, 2025 10:48 ET | Source: Janssen Cilag International NV

New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma

Sustained MRD negativity (10-5) rates at 24 months or longer were more than doubled in transplant eligible patients treated with daratumumab-VRd vs VRd alone in the Phase 3 PERSEUS study1 Data from...
June 03, 2025 10:45 ET | Source: Janssen Cilag International NV

Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1 Data show a nearly 50 percent reduction...